AstraZeneca is a global biopharmaceutical giant, dedicated to the discovery, development, and commercialization of prescription medicines. Its portfolio spans a wide range of areas including cardiovascular, renal, metabolism, oncology, and treatments for rare diseases and COVID-19. The company is known for leading products like Tagrisso, Imfinzi, and Lynparza, among others. AstraZeneca not only serves healthcare professionals and patients worldwide but also engages in significant collaborations, such as with Neurimmune AG, to push the boundaries of medicine. Headquartered in Cambridge, UK, AstraZeneca continues to be at the forefront of addressing global health challenges.
Novartis just handed the entire Lp(a) drug class a failing grade, and Amgen is taking the worst of the punishment despite releasing promising trial results of its own on the very same…
Wall Street analysts reshuffled the deck on Monday with a wave of upgrades, downgrades, and fresh initiations spanning pharma giants, fast-casual chains, and streaming players. Find out which names got bullish bets…
Kailera Therapeutics raised one of the biggest obesity biotech IPOs in recent memory, then watched its stock drop nearly 30%. Now several of the world's largest drugmakers have a compelling reason to…
BioCryst just turned profitable, its HAE drug Orladeyo is minting cash, and a rival's blockbuster acquisition just put the whole rare-disease sector in play. So which pharma giant has the most to…
A Mizuho healthcare analyst says merging two of pharma's biggest names could unlock a fortune, but the math only works if one brutal condition is met.
Geopolitical relief triggered a sharp selloff in oil and a Treasury retreat, handing bulls an opening to reclaim momentum at the start of August, but a surprise move from MicroStrategy and a…
The FDA just approved the first once-daily oral PCSK9 pill, and five major stocks now sit in the crosshairs. Not all of them come out ahead, and the biggest surprise winner may…
Eli Lilly (NYSE:LLY | LLY Price Prediction) is finally acting like a trillion-dollar drugmaker again. After a brutal stretch in late 2025 and a wobbly start to this year, the stock punched…
Franklin FTSE International Low Volatility High Dividend Index ETF (NYSEARCA:LVHI) closed Friday at $41 after a quarterly distribution cycle that continues to deliver the income international dividend investors buy this fund for.…
The iShares Core MSCI EAFE ETF (NYSEARCA:IEFA) has quietly become one of the year’s standout core holdings, trading near $97 after a 8% year-to-date run and a 22% one-year gain. With $169.6…
Dividend income arrives whether markets rally or sell off. For investors seeking recurring cash flow, high-yield equities remain the cleanest source outside a paycheck. They settle in cash, clear immediately, and can…
Our AstraZeneca (NASDAQ:AZN | AZN Price Prediction) call comes one day after the British drugmaker reported Q1 2026 revenue of $15.29 billion, up 13% year over year, and reaffirmed full-year guidance. With…
Vandita Jadeja International developed-market equities have outperformed US large caps through the first four months of 2026. The S&P 500 is up about 4.5% year to date, while three of the most widely held…
Pre-Market Stock Futures: Risk-on appeared back, at least for the last two days, as the stock market put together another rally on Wednesday, with hopes for an end to the war in…
AstraZeneca PLC (NASDAQ:AZN | AZN Price Prediction) has delivered a solid trailing 12 months, with shares up 31.43% over the past year. Year-to-date, the stock has gained 6.02%, though it has pulled…
Joel South 
